Most researchers trying to source CJC-1295 in Sitou soon discover that local retail options are essentially nonexistent. This global online supply model is actually an advantage for quality — top vendors differentiate through analytical documentation in ways no local retailer can match. A properly operating CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. Use this guide to verify vendor quality systematically — the quality evaluation approach outlined here work regardless of your location.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Sitou comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Before assessing any particular supplier, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Strong quality indicators beyond COA quality: documented vendor history spanning multiple years, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. The dry lyophilised powder of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Sitou
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Lyophilised CJC-1295 should be frozen at −20°C as soon as it arrives; do not freeze and thaw reconstituted CJC-1295 multiple times by preparing small aliquots before storage. The main safety concern arising from sourcing in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the specific protection against this risk. Protocol documentation — documenting product details, dates, and administration precisely — is a research best practice for CJC-1295 that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
